tumor types, including hemato- logical (blood) cancers, colorec- tal cancer, endometrial cancer, breast cancer, and glioblastoma. They are in the process of estab- lishing RNA modifications as a main, fundamental mechanism of gene expression regulation, and also hope to develop technologies that can directly benefit patients and clinical practices. Additionally, multiple Comprehensive Cancer Center investigators are currently working with He on biomarker cancer discoveries using the new 5-hmC DNA modification detec- tion technology. “This research laid down the mech- anistic pathways for our current understanding of how these modifications impact biological outcomes, including those related to cancer,” He says. “Cancer and other diseases can hijack aberrant RNA methylation to gain a survival advantage, allowing cells to prolif- erate and grow out of control.” He was recently recognized for his groundbreaking work with the 2017 Paul Marks Prize for Cancer Research, a prestigious recognition of promising investi­ gators aged 45 or younger for their efforts in advancing cancer research. Chuan He, PhD, was awarded the 2017 Paul Marks Prize for his work in DNA and RNA epigenetics. He’s team is in the process of establishing RNA modifications as a main, fundamental mechanism of gene expression regulation, and also hope to develop technologies that can directly benefit patients and clinical practices. 11